Aristidis Veves, Beth Israel Deaconess Medical Center, to speak at GTCbio's Diabetes Summit
Aristidis Veves, Professor of Surgery at Beth Israel Deaconess Medical Center will speak on "Novel Therapeutic Targets & Strategies for Diabetic Foot Ulceration and Peripheral Neuropathy" at GTCbio's 2016 Diabetes Summit.
- (1888PressRelease) March 29, 2016 - Dr. Aristidis Veves is the Director of the Rongxiang Xu, MD, Center for Regenerative Therapeutics, the Research Director of the Joslin-Beth Israel Deaconess Foot Center and the Microcirculation Lab, and Professor of Surgery at Harvard Medical School. His main academic interest is diabetes complications including cardiovascular disease, neuropathy and foot ulceration. He conducts 'bench to bedside' research that is mainly funded by the National Institute of Health (NIH). The main aim of his research is to understand the pathogenesis of these complications can develop new therapeutic approaches.
In Dr. Veves' presentation, "Novel Therapeutic Targets & Strategies for Diabetic Foot Ulceration and Peripheral Neuropathy", he states:
Fifteen percent of diabetic patients are expected to develop diabetic foot ulceration (DFU) within their lifetime. With the expected increase of incidence of diabetes, DFUs will represent an even bigger burden for the healthcare system of both developed and developing countries and may prove to be one of the most costly complications of diabetes. Although there is some overlap, acute normal wound healing can be divided in three phases: coagulation-inflammation, proliferation and remodeling. Chronic wounds, like the DFU, lack this linear progression from one phase to the next and are mainly characterized by the persistence of the inflammatory phase, although progression to the proliferation phase may be present in certain wound areas. Substance P and mast cells (MC) are involved in different phases of wound healing.
Diabetes and the associated SP deficiency are associated with an absence of an acute inflammatory response important for wound healing progression and cause a persistent inflammation through all the healing process. SP treatment induces an acute inflammatory response which enables the progression to the proliferative phase and modulates macrophage activation towards the M2 phenotype that promotes wound healing. In addition, the number of degranulated MCs is increased in unwounded forearm and foot skin of DM patients, and unwounded dorsal skin of DM mice. Conversely, post-wounding MC degranulation increased in non-DM but not in DM mice. Pre- and post- wounding mice treatment with MC stabilizers rescues the DM-associated wound healing impairment in mice and shifts macrophages to the regenerative M2 phenotype.
We invite you to attend the 2016 Diabetes Summit, which will take place April 25-27, 2016 in Boston, MA to listen to Dr. Veves' talk and many other leaders in the field including Camillo Ricordi from University of Miami and Alexander Fleming from Kinexum!
This summit features the following two conferences:
1) 9th Diabetes Drug Discovery & Development Conference
2) 6th Diabetes Partnering & Deal-Making Conference
For more information, please visit www.gtcbio.com/diabetes or contact us using the information below.
GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio ( @ ) gtcbio dot com
Phone: (626) 256-6405
Fax: (626) 466-4433
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam